Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.50 |
| ▸ | CASP6 | P55212 | 15/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 15/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897560 | 0.91 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL4552820 | 0.91 | CASP3 (0.51) | CASP3CASP6CASP8 | |
| SCHEMBL1893933 | 0.86 | CASP3 (0.57) | CASP3CASP6CASP8 | |
| SCHEMBL4556858 | 0.85 | CASP3 (0.62) | CASP3CASP6CASP8 | |
| SCHEMBL4556364 | 0.82 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL4556832 | 0.82 | CASP3 (0.56) | CASP3CASP6CASP8 | |
| SCHEMBL15949720 | 0.81 | CASP3 (0.42) | CASP3CASP6CASP8 | |
| SCHEMBL4556879 | 0.81 | CASP3 (0.59) | CASP3CASP6CASP8 | |
| SCHEMBL4556825 | 0.81 | CASP3 (0.57) | CASP3CASP6CASP8 | |
| SCHEMBL1898227 | 0.80 | CASP3 (0.58) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091910-B1 | CRYSTALLINE FORMS OF (3 S) -3- [N- (N' - (2-TERT-BUTYLPHENYL) OXAMYL) ALANINYL] AMINO-5- (2 ', 3 ', 5 ', 6 ' -TETRAFLUORO PHENOXY) -4-OXOPENTA NOIC ACID | CONATUS PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-7692038-B2 | Crystalline forms | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080249031-A1 | Of (3S)-3-[N (N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid; liver fibrosis | PFIZER, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249031-A1 | Of (3S)-3-[N (N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid; liver fibrosis | OTC, PYGL, SLC10A1 | CASP3 1425/4885CASP6 1463/4885CASP8 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.